Fri, January 6, 2023
Thu, January 5, 2023
Wed, January 4, 2023
Tue, January 3, 2023
Fri, December 30, 2022
Thu, December 29, 2022
Wed, December 28, 2022
Tue, December 27, 2022
Fri, December 23, 2022
Thu, December 22, 2022
Wed, December 21, 2022
Tue, December 20, 2022

Derek Archila Maintained (ASND) at Buy with Increased Target to $177 on, Jan 3rd, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-177-on-jan-3rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Derek Archila of Wells Fargo, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $169 to $177 on, Jan 3rd, 2023.

Derek has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with Derek's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Derek


  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Increased Target to $148 on, Tuesday, November 15th, 2022
  • Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $164 on, Monday, November 14th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $148 on, Monday, November 14th, 2022
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $163 on, Thursday, November 3rd, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $130 on, Thursday, November 3rd, 2022
  • Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $174 on, Thursday, October 20th, 2022

Publication Contributing Sources